NCT07330076尚未招募2 期
Protocol for a Prospective, Single-arm, Multicenter Clinical Study on the Efficacy and Safety of Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 28
- 主要终点
- 3-year DFS rate
研究概览
简要总结
The primary objective is to evaluate the efficacy and safety of Iruplinalkib Tablets as postoperative adjuvant therapy in patients with stage IA, ALK-positive NSCLC with high-risk factors.
详细描述
This Prospective, Single-arm, Multicenter Clinical Study aims to evaluate the Efficacy and Safety of Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC with High-risk Factors.This study consists of three phases: screening, treatment, and follow-up.Efficacy evaluation and safety monitoring should be performed throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- 1.Age ≥18 years, male or female. 2.ECOG Performance Status (PS) score: 0-
- •3.Expected survival ≥12 weeks. 4.Histologically or cytologically confirmed non-small cell lung cancer. 5.ALK-positive status confirmed by the investigator (NGS). 6.Clinical stage IA (maximum tumor diameter ≤3 cm, AJCC 9th edition). 7.No prior treatment with any ALK TKI targeted therapy. 8.The patient has undergone curative-intent tumor resection (sublobar resection, lobectomy, sleeve resection).
- •9.Organ function meets the following requirements (use of any blood products or hematopoietic growth factors within 14 days prior to enrollment is not allowed):
- •Hemoglobin ≥90 g/L;
- •White blood cell count ≥3.5 × 10⁹/L;
- •Absolute neutrophil count ≥1.5 × 10⁹/L;
- •Platelets ≥80 × 10⁹/L;
- •AST, ALT ≤2.5 × ULN; if liver metastases are present, AST, ALT ≤5 × ULN;
- •Total bilirubin (TBIL) ≤1.5 × ULN;
- •Urea/BUN and creatinine (Cr) ≤1.5 × ULN (and creatinine clearance (CCr) ≥50 mL/min);
- •Left ventricular ejection fraction (LVEF) ≥50%. 10.Patients of childbearing potential/fertile males must agree to use effective contraception.
排除标准
- •1.Presence of pathological components other than non-small cell carcinoma in tissue or cytology.
- •2. History of allergy to ALK TKI agents or their ingredients.
- •Poorly controlled underlying diseases before enrollment, such as coronary artery disease, heart failure, cerebral infarction, hypertension, chronic obstructive pulmonary disease, interstitial lung disease, rheumatic diseases, peptic ulcer, etc. (to be determined by the investigator's assessment).
- •4. Active pulmonary tuberculosis (TB), active tuberculosis infection, or active syphilis infection; eligibility for the clinical trial may be reassessed after the condition is stably controlled.
- •5. Positive anti-HIV test; positive hepatitis B surface antigen (HBsAg) with HBV-DNA above the upper limit of normal; active hepatitis C virus (HCV) infection.
- •6. Serious infection within 4 weeks prior to the first dose, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic anti-infective therapy within 2 weeks prior to the first dose (excluding antiviral therapy for hepatitis B or C).
- •7. Psychiatric disorders or social conditions that limit the subject's compliance with study requirements or affect their ability to provide written informed consent.
- •8. Any arterial thromboembolic event within 6 months prior to the first dose, venous thromboembolic events of Grade 3 or above, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 3 months prior to the first dose.
- •9. History of severe bleeding tendency or coagulation dysfunction; obvious active bleeding within 1 month prior to the first dose (to be determined by the investigator's assessment).
- •10. History of drug abuse, alcohol abuse, or substance abuse.
- •Pregnant or lactating women.
- •Patients deemed unsuitable for participation in this study by the investigator.
研究组 & 干预措施
Iruplinalkib Tablets
Experimental
干预措施: Iruplinalkib tablets (Drug)
结局指标
主要结局
3-year DFS rate
时间窗: Up to 36 months
Defined as the proportion of patients who have not experienced disease progression or death from any cause from the initiation of Iruplinalkib treatment until the end of the third year.
次要结局
- Overall Survival (OS)(Time Frame: up to 36 month)
研究者
相似试验
招募中
4 期
Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic SurgeryNCT07269106Zhongshan Ophthalmic Center, Sun Yat-sen University204
撤回
2 期
Zimberelimab + Domvanalimab in Gastroesophageal AdenocarcinomaNCT07283848Massachusetts General Hospital28
招募中
2 期
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIGBMGliomaNCT07326566Black Diamond Therapeutics, Inc.162
招募中
3 期
A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administration of local anesthetic intraperitoneally/perioperatively in advanced epithelial ovarian cancer - IPLA-OVCA2023-507732-20-00Karolinska University Hospital, Karolinska University Hospital220
招募中
2 期
Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric CancerNCT07325630Zhejiang Cancer Hospital60